Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Suzanne E. Wardell(Duke University), Shunqiang Li(Washington University in St. Louis), John D. Norris(Duke Medical Center), Stephen G. Dann(Pfizer (United States)), Koleen Eisele, Robert G. Crowder(Knoxville College), Matthew J. Ellis(University of California, Davis), Kim Arndt(Pfizer (United States)), Todd VanArsdale(Pfizer (United States)), Donald P. McDonnell(Duke University), Holly M. Alley(Duke University), Elizabeth Griffin, Jinping Lai(Fujian Medical University), Jieya Shao(Washington University in St. Louis), Tina Primeau(James S. McDonnell Foundation)
Cited by 0
Related Papers
A tutorial review of economic model predictive control methods
|Journal of Process Control|2014|711
Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
|Cell Reports|2013|630
International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors
|Pharmacological Reviews|2006|430
Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels
|Molecular & Cellular Proteomics|2014|419
Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer
|Nature Communications|2021|336